10-KPeriod: FY2024

Astera Labs, Inc. Annual Report, Year Ended Dec 31, 2024

Filed February 14, 2025For Securities:ALAB

Summary

Astera Labs, Inc. (ALAB) has demonstrated exceptional revenue growth in fiscal year 2024, with a 242% increase compared to 2023, reaching $396.3 million. This surge is primarily driven by increased unit shipments of their Aries products and a more favorable product mix leading to higher average selling prices. The company has also significantly improved its gross margin, climbing to 76.4% in 2024 from 68.9% in 2023, largely due to reduced inventory write-downs. Despite the strong top-line performance, Astera Labs continues to operate at a net loss, which widened in 2024 to $83.4 million from $26.3 million in 2023. This increased loss is significantly influenced by a substantial rise in operating expenses, particularly non-cash stock-based compensation, which surged by $223.1 million related to RSUs vesting upon their IPO. The company's robust cash position, bolstered by the March 2024 IPO which generated $672.2 million in net proceeds, provides ample liquidity to fund operations and future investments. Astera Labs expects its current cash resources to be sufficient for at least the next 12 months.

Financial Highlights

51 data points
Beta

Revenue

$396.29M

76.4% Gross Margin

Net Income

-$83.42M

-21.1% Net Margin

EPS (Diluted)

$-0.64

Total Assets

$1.05B

Cash & Equivalents

$80.04M

Free Cash Flow

$102.43M

Financial Statements
Beta
Revenue$396.29M
Cost of Revenue$93.59M
Gross Profit$302.70M
R&D Expenses$200.83M
Operating Expenses$418.76M
Operating Income-$116.07M
Net Income-$83.42M
EPS (Basic)$-0.64
EPS (Diluted)$-0.64
Shares Outstanding (Basic)131.26M
Shares Outstanding (Diluted)131.26M

Key Highlights

  • 1Revenue surged by 242% to $396.3 million in fiscal year 2024, up from $115.8 million in 2023, driven by increased unit shipments and average selling prices.
  • 2Gross margin improved significantly to 76.4% in 2024, up from 68.9% in 2023, primarily due to a reduction in inventory write-downs.
  • 3The company experienced a substantial increase in operating expenses, with a 283% rise in 2024, largely driven by $223.1 million in non-cash stock-based compensation expenses related to IPO vesting conditions.
  • 4Net loss increased to $83.4 million in 2024 from $26.3 million in 2023, primarily due to the surge in operating expenses.
  • 5The company completed its Initial Public Offering (IPO) in March 2024, raising $672.2 million in net proceeds.
  • 6As of December 31, 2024, Astera Labs held $914.3 million in cash, cash equivalents, and marketable securities, providing strong liquidity.
  • 7The company has a significant customer concentration, with two customers accounting for 60% of 2024 revenue and 37% of accounts receivable.

Frequently Asked Questions

Astera Labs designs and delivers semiconductor-based connectivity solutions for cloud and AI infrastructure. Their 'Intelligent Connectivity Platform' integrates hardware (ICs, boards, modules) and software (COSMOS) to address data, network, and memory bottlenecks in high-performance computing environments, primarily serving hyperscalers and system OEMs.

The company has shown explosive revenue growth, increasing by 242% to $396.3 million in 2024. Gross margins also improved significantly. However, the net loss widened due to a large increase in operating expenses, notably stock-based compensation related to the IPO. Despite the net loss, the company ended the year with a strong cash position.

Astera Labs does not currently expect to declare or pay any cash dividends on its common stock for the foreseeable future. The company intends to retain all available funds and future earnings for business operations and growth initiatives. Investors seeking dividends are advised against purchasing Astera Labs' common stock.

The filing mentions provisions in charter documents and Delaware law that could delay or prevent a change of control. It also notes the potential adverse impact on stock price if securities analysts do not publish research or publish unfavorable research. Additionally, the company has identified material weaknesses in its internal control over financial reporting, which are in the process of being remediated.